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Summary
C.B-17 severe combined immune deficient (SCID) mice, which lack functional B and T lymphocytes,
allow xenografts and, therefore, can be used to study the biology of human malignancies. Two
different human B cell lymphoma cell lines, SU-DHL4 and OCI-Ly8, which both harbor the
t(14;18) chromosomal translocation, were injected into C.B-17 SCID mice. Mice injected
intravenously or intraperitoneally developed tumors and died in a dose-dependent manner. The
presence of tumor cells in various murine tissues could be demonstrated by a clonogenic tumor
assay, staining of frozen sections with a monoclonal antibody (mAb) against a human B cell
antigen (CD19), and with the polymerase chain reaction technique.
A protocol using cytotoxic effector cells was developed and used to selectively deplete the tumor
cells from bone marrow. These cells were developed by growing peripheral blood mononuclear
cells in the presence of interferon y (IFN-y), anti-CD3 mAb, and interleukin 2 (IL2). The timing
of IFN-y treatment was critical and optimal if IFN-y was added before IL2 treatment. The
cells that were stimulated by IFN-y, followed by IL2, could be expanded by treatment with
a mAb directed against CD3. These cells could be further activated by IL1, but not by tumor
necrosis factor a. With this protocol, a tumor cell kill of 3 logs was obtained as measured by
a clonogenic assay. Interestingly, despite their high cytotoxic activity against lymphoma cells,
these cells had little toxicity against a subset of normal human hematopoietic precursor cells
(granulocyte/macrophage colony-forming units). These cells were further tested by treating murine
bone marrow contaminated with the human lymphoma cell line SU-DHL4, and injecting these
cellsinto SCID mice to assay for tumor growth in vivo. The animals injected with bone marrow
contaminated with SU-DHL4 cells had enhanced survival if the bone marrow was treated with
the cytokine-induced killer cells before infusion. The SCID mouse provides a useful in vivo model
for evaluation of new therapeutic approaches for lymphoma treatment. The cytokine-induced
killer cells generated as described here could have an important impact on bone marrow purging
for autologous bone marrow transplantation as well as for adoptive immunotherapy.
T
he culture ofnormal human lymphocytes with 11,2 results
in the generation_ of cytotoxic cells that lyse a variety
of tumor cell lines as well as fresh autologous tumors (1).
These cells effectively lyse tumor cells that are refractory to
NKmediated lysis, and have been termed lymphokine-activated
killer (LAK)t cells. LAK cells offer a potential for adoptive
immunotherapy (2). Phenotypically, most of the LAK pre-
cursor and effector cells express surface NK markers. The use
1 Abbreviations used in this paper. BM, bone marrow; CIK, cytokine-
inducedkiller; hu, human; LAK, lymphokine-activated killer; TIL, tumor-
infiltrating lymphocytes.
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of LAK cells in immunotherapy is hampered by the need for
large numbers of cells and their inherent low cytotoxic ac-
tivity. High cell number and high cytotoxicity are required
to produce effective tumor reduction, as has been shown in
animal models (3). Recently, there have been reports of the
generation of more efficient cytotoxic cells (3, 4). These cells,
termed tumor-infiltrating lymphocytes (TIL; 3), have T cell
markers. Problems encountered in TIL cell preparation are
the small number of recovered cells from tumor biopsies, as
well as the possibility that there may be alterations in func-
tion during extraction from human tissue (5). Prior studies
have indicated that cytotoxic cells can be expanded by cul-
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Volume 174 July 1991 139-149turing PBMC in the presence of anti-CD3 mAb (4). In this
study, we report an improved protocol for the generation
of high numbersof effector cells that have increased cytotox-
icity against human B lymphoma cell lines.
To study the in vivo effects of these cells, a SCID mouse/
human lymphoma model system was developed. C.B-17
SCID/SCID mice have been used as a model to study lym-
phocyte function and differentiation at the cellular and mo-
lecular level (6-9). These mice, which are congenic partners
of BALB/cAn, lack functional T and B lymphocytes (10).
The mutation in these mice occurs on chromosome 16 (11).
In theseanimals, the genesencoding antigen-specific receptors
on B and T cells do not rearrange (12, 13), as they normally
would during differentiation. NK cells appear to be func-
tional since spleen cellsfrom C.B-17 SCID mice exhibit NK
activity against YAC lymphoma target cells in a s'Cr release
assay (14) . Lymphoid tissue can be reconstituted with intra-
venous injection of precursors contained in histocompatible
bone marrow from congenic BALB/c donors (15). SCID mice
can be used as a murine model for the analysis of human
hemato-lymphoid differentiation and function, since human
fetalliver, thymus, andlymph node cellsengraftin thesemice
(9). These SCID-hu mice have been infected with HIV-1 as
a murine modelfor the acute infection phase of AIDS (16, 17).
Human cell lines and fresh tumor samples will grow into
tumors in SCID mice (18-23). Onemajoradvantageof SCID
mice as compared with nude mice as tumor models is the
possibility ofexamining theinteraction betweenhumanlym-
phocytes and human tumors in SCID mice (9, 22). The
cytokine-induced killer (CIK) cells generated in this study
have been used to deplete human tumor cells from bone
marrow and enhance survival of SCID mice injected with
bone marrow contaminated with human tumor cells. The
presence of the tumor cells could be monitored by t(14;18)
PCRassay of murine tissues, as well as morphologic andim-
munophenotypic techniques.
Materials and Methods
Isolationand CultureofLAKCellsandCIKCells.
￿
HumanPBMC
were separatedby Ficoll density gradient centrifugation. Adherent
cells were removedby adherence to plastic surfaces, Nonadherent
cells were resuspended in complete medium consisting of RPMI
1640 (Applied Scientific, San Francisco, CA), 10% FCS (HyClone
Labs, Logan, UT), 25 mM Hepes, 2 MM L-glutamine, 100 U/ml
penicillin, 100,ug/ml streptomycin, and50 AM 2-ME. HumanrIL2
(Cetus Corp., Emeryville, CA) was added at 300U/ml on day0.
Cells were cultured at a concentration of 106/ml. Cultures were
incubated at 37°C in a humidified atmosphere of 5% CO2. Cell
density was determined every 3 d, and cells were subcultured in
fresh complete medium and IL2 at 2 x 105 cells/ml.
To generate CIKcells, 1,000U/ml humanrIFN--y (Genentech,
South San Francisco, CA)was addedon day 0. After 24 h ofincu-
bation, 50 ng/ml mAbagainst CD3 (38.1; Dr. P. Martin, Univer-
sity ofWashington, Seattle, WA), 300 U/ml 11,2, and 100U/ml
of human rIIA (Genzyme, Boston, MA) were added. Fresh IL2
and fresh medium were added every3 d. Thesecells were termed
CIK cells.
"Cr Release Cytotoxicity Assay.
￿
Two B lymphoma cell lines,
OCI-Ly8 (24) and SU-DHL4 (25), were used and "Cr release cy-
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totoxicity assays performed as reported recently (26). Lytic units
(LU) were calculated from cytotoxic titration curves as described
previously (27).
Clonogenic TumorAssay.
￿
In this assay, limiting numbersofSU-
DHL4 cellswere plated in methylcellulose. The tumorcellswere
cultured in IMDM with 15% FCS, 0.9%BSA(ArmourPharmaceu-
ticalCo., Tarrytown, NY), 50 jLmol/12-ME, 1% penicillin/strep-
tomycin, 1% L-glutamine, andmethylcellulose(final concentration
1.1%). Cultures were plated in 0.25-ml volumes in Mark II tissue
culture plates (Costar, Cambridge, MA). All assays were done in
duplicate. Colonies were counted after 7 and 14 d.
Staining ofEffector Cells.
￿
Effector cellswere stained with anti-
bodies against Leu-2 (CD8) andLeu-3 (CD4), coupled to PE, and
against Leu-11 (CD16), coupled to FITC (antibodies from Becton
Dickinson & Co., Mountain View, CA). Anti-mouse K-PE and
anti-Lyt-1-FITC mAbs were used as negative controls. Cellswere
incubated with the antibodies for 30 min at 4°C, excess antibody
was removed, thecells were washed, and flow cytometrywas per-
formed.
Granulocyte/Macrophage Colony-forming Units(CFU-GM) Assay.
Bone marrow mononuclear cells (BM-MNC) (2 x 105 cells/ml)
that were depleted of monocytes were cultured in IMDM with
15% FCS, 0.9% BSA (Armour Pharmaceutical Co., Tarrytown,
NY), 50 iLmol/liter 2ME, 1% penicillinAtreptomycin, 1% L-glu-
tamine, and methylcellulose (final concentration, 1.1%). Placental
conditioned medium (PCM)wasaddedto control cultures at afinal
concentrationof 15% as an exogenous CSF source. Cultures were
plated in 0.25-ml volumesin Mark II tissue culture plates (Costar).
After 10 dof incubation in humidified 5% COz at 37°C, the cul-
tures were examined under an inverted microscope and CFU-GM
colonies scored.
Animals. BALB/c.C57BL/Ka-Igh-1/ICR male mice, which
were 7-10 wk old, were obtained from theFoxChaseCancer Center,
Philadelphia, PA, through Dr. M. Lieberman, Stanford Univer-
sity, Stanford, CA. The mice were kept on trimethoprim and sul-
famethoxazole (Sulfatrim), andchlorinated water ad libitum since
birth. Aseptic procedures were used routinely.
TumorInoculation.
￿
For a dose titration experiment, a total of
28 mice were injected either intravenously or intraperitoneallywith
humanlymphoma cells. 19 animalsreceived various dosesof viable
SU-DHL4 cells (0.5-100 x 106), and nine received OCI-Ly-8
cells. Tumor cells were in log phase of growth when injected.
Animals injected intravenously also received 10 U/ml of heparin
per ml. Four animals received 175 cGy ofwhole body irradiation
(250 kV, 15 mA; Philips MedicalSystems Inc., Shelton, CT), which
delivered X-rays at arate of 59 rad/min. Thedistance between source
and skin was 60 cm and 0.25 mm Cu, and 1-mm Al correction
filters were used.
TumorHistopathology.
￿
Frozen sections were prepared from ex-
cisedtumors by standard techniques. Thespecimenswere snap frozen
in OCT compound (Miles Inc., Elkhart, IN) and stored in liquid
nitrogen. Sections were cut in acryostat microtome (ReichertJung,
Buffalo, NY), placed on slides coated with 1% gelatin, and fixed
in acetoneat -20°Cfor at least 20 h. Sections were stained either
with hematoxylin or with mAbs (see below) and mounted with
glycergel(DakoCorp., Carpiteria, CA). Frozen sections of excised
tumor, spleen, lung,bone marrow, andliverwere stainedwith Len-
12 (CD19) biotin-conjugated mAb(BectonDickinson&Co.). Leu-4
(CD3; diluted 1:100)biotin-conjugated antibody was used as anega-
tive control. Staining wasperformedby incubation with streptavidin
alkaline phosphatase (Caltag Lab., South San Francisco, CA) for
1 h, I mg/mloffast red TR salt (4-chloro-2-methyl-aniline; Sigma
Chemical Co., St. Louis, MO), 0.2 mg/ml of naphthol ASMXphosphate (Sigma Chemical Co.) and 1 mM levamisole (Sigma
Chemical Co.) (28).
To determine the optimal concentration of the mAb against
biotin-conjugated Leu-12, a titration of this antibody was performed
with human lymph node tissue. A 1:20 dilution of the antibody
was found to be optimal and used for further experiments.
Polymerase Chain Reaction (PCR).
￿
Murine tissue from various
organs was cut into small pieces and either directly used for DNA
extraction or frozen with OCT compound (Miles Inc.) in liquid
nitrogen and stored at -70°C. For DNA extraction, mortar and
pestle were used to break the tissues into smaller pieces in the pres-
ence of liquid nitrogen. The ground powder was washed twice
with PBS before standard phenol-chloroform extraction and eth-
anol precipitation ofDNA were performed. 2-5 jig of DNA was
used for each PCR. The consensus Ig J,, oligonucleotide (MC4)
and the bcl-2-specific oligonucleotide (MC5) were used. Two 0
actin oligonucleotides, termed actin 1 and 2, were used as a control
of the PCR reaction in some cases (29). The PCR was performed
as described recently (26). The internal oligonucleotide MC6 and
one of the actin primers were end labeled with [32P]ATP and used
for detection.
Bone Marrow Purging.
￿
SCID mice were irradiated to the long
legs with 400 cGy. The rest of their bodies were shielded with
lead. Either 106 or 10' viable SU-DHL4 cells were incubated with
cytotoxic effector cells at a ratio of 20:1 E/T cells. For the genera-
tion of effector cells, peripheral blood was drawn from EBVnegative
donors. Before use in vivo, cytotoxicity of the effector cells was
tested in a "Cr release assay. As a control, no effector cells were
added. To model purging of human bone marrow, 10' bone
marrow cells from BALB/c or SCID mice were also added. IL-2
was present during the co-incubation period. Cellswere incubated
at 37°C in 5% COz for 24 h .
These cell mixtures were injected intravenously into SCID mice
3-48 h afterirradiation. 10 U/ml heparin was added and the cells
were filtered through a nylon mesh immediately before injection.
Cells were injected slowly over 5 min. Cell doses of >101 cells
were split into two equal doses and injected 24 h apart. Animals
were monitored daily for tumor growth.
Engraftment ofBALBlc Bone Marrow.
￿
4 wk after injection, pe-
ripheral blood from animals injected with BALB/c bone marrow
cells was monitored for evidence of engraftment. The mAb AMS
9.1 was titrated before use. Peripheralblood was taken from these
mice, and Ficoll-separated cells were stained for BALB/c IgD H
chain allotype using thebiotin-labeled mAb AMS 9.1(30) at a final
concentration of 1:4. Streptavidin coupled to PE (1:40) was used
as a second stageantibody. Cellswere analyzed on a FACS® (Becton
Dickinson & Co.).
Statistical Analysis.
￿
Results were analyzed for statistical sig-
nificance by using the Student's t test.
Results
Ejector Cells.
￿
Cytotoxic effector cells were generated from
PBMC by incubating the cells in the presence ofIL2. A mAb
directed against CD3 was used as a mitogenic stimulus to
these cells. Fig. 1 shows the expansion of cells cultured in
IL2 alone or with the addition of the anti-CD3 mAb. Cells
cultured in IL-2 alone had a 19-fold increase in cell number
by day 15. Cells cultured with IL2 plus anti-CD3 had a 754-
fold increase by day 15. The addition of IFN-y and IL-I had
no effect on cell proliferation as determined by a [3H]thymi-
dine incorporation assay on day 21 (data not shown).
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Figure 1.
￿
Addition of anti-CD3 mAb has a proliferative effect on PBL.
PBL were cultured at 106 cells/ml at 37°C in 5% C02, and recultured
every 3 d with medium and 11,2. Proliferation ofPBL from five patients
in long-term culture in complete medium with IIr2 alone, IL2 plus anti-
CD3, or 11,2, anti-CD3, IFN-y, and IIA is shown. Results are presented
as mean value ± SEM.
Despite the positive effect on cell proliferation by anti-CD3,
these cells had similar cytotoxic activity on a per cell basis
(lytic units per 106 cells), as determined by "Cr release and
tumor clonogenic assays. However, because of the increase
in cell number, the totallytic units per culture was increased
N45-fold (Table 1).
In an attempt to enhance the cytotoxic activity of these
cells, various recombinant cytokines, including IFN-y, IL1,
and TNF (Cetus Corp., Emeryville, CA) were added to the
cell cultures. The effect ofIFN-y on cytotoxic activity, when
given simultaneously or sequentially to IL2, is shown in Fig.
2. IFN-y addition resulted in an increase in cytotoxic activity
only if added 24 h before the addition of 11.,2. ILA alone had
no effect on cytotoxic activity, but there was an increase in
activity when combined with IFN and anti-CD3, as mea-
sured by the 5'Cr release assay (Table 1). This was also true
for the tumor colony assay, where this combination, termed
CIK cells, proved to be the most effective. Further addition
of TNF had no effect. Because of the increase in cytotoxicity
and high proliferative response, CIK cells had a 73-fold in-
crease in total lytic units per culture as compared with stan-
dard IL-2-stimulated LAK cells. In a tumor colony assay, these
cells were capable ofgenerating a log cell kill of 2.5-3.5 (Table
1). This represents an additional increase of about 2 logs of
tumor cell kill as compared with standard LAK cells. Cell
number peaked at -21-28 d, and maximal activity was no-
ticed between days 10 and 28.
To exclude the possibility that the increase in cytotoxic ac-
tivity could be due to a rapid proliferation of a subpopula-
tion of cells, a [3H]TdR incorporation assay was performed.
None of the lymphokines added on day 12 induced a prolifer-
ativeresponse on day 14 above that achieved by IIr2 plus anti-
CD3 (data not shown). This suggests that these cellsachieved
higher cytotoxic activity on an individual cell basis, or that
inactive cells are newly recruited to become cells with cyto-
toxic activity.
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200Human PBMC were cultured for 15 d in media containing IL-2 (300 U/ml) alone (LAK cells) or additional stimuli. Additional stumuli included
anti-CD3 mAb 38.1 (IL-2 plus anti-CD3) or IFN-y on day 0, followed by IL-2, IL-1, and 38.1 on day 1 (CIK cells). Cells were cultured at a
concentration of 106 cells/ml. IL-2 andmediawere changedevery 3 d. Allcultures were tested for cytotoxicity in a S1Cr release assay against OCI-
Ly8 cells on day 15. According to Ochoa et al. (4), total lytic units (LU) per culture were calculated by multiplying the number of LU/106 cells
by the totalnumber of cells that have been present in theculture at that time. Logcell kill wasdetermined usinga clonogenic tumor assay. Limiting
numbers (2,000-256,000) of cells of SU-DHL-4 were incubated for 24 h with the addition of cells from the various protocols at an E/T ratio of
20:1, and then plated in 1.1% methylcellulose. Colonies were counted after 7 and 14 d. Control plates consisted of SU-DHL-4 cells without the
addition of cells from the various protocols andoftumorcells plus untreatedPBL. Thetable represents data from five different experiments. Results
are presented as mean value ± SEM.
As shown in Table 2, the increase in cytotoxic activity had
little toxic effect on normal human bone marrow cells. CFU-
GM activity of human bone marrow cellswas only partially
impaired (75% of control) when the different kinds of cyto-
toxic effector cells were tested.
Cells generated according to the most effective cytotox-
icity protocol were studied by flowcytometry analysis after
14 d. The majority of these cells were positive for T cell
markers (TCR-a/o and CD4 or CD8) . About 10% of the
cells were positive for CD16 (SchmidtWolf et al., manuscript
in preparation).
IL-2
IL-2 +
anti-CD3 + IL-1
IL-2 + anti-CD3 + IL-1 +
IFNy24 hrs prior to IL-2
p :9 .05
Figure 2.
￿
Influenceof sequence of IFN-y on the cytotoxic activity in
combination with other cytokines. PBL were cultured with 11,2 alone,
IL2 plus anti-CD3 plus 114, IFN-y 24 hbefore IL2 plus anti-CD3 plus
ILl, IFN-ygivensimultaneously with IL2plus anti-CD3 plus IL1, and
IFN-y added24 hafteraddition of 11,2 plus anti-CD3 plus ILl. A s1Cr
release assaywasperformedon day15. Resultsarepresentedas mean value
± SEM. pvalues of each protocol were calculated by comparinglytic units
from each protocol with lyricunitsfrom the protocol in thetopbar(IL2
alone). The figure represents data from two separate experiments.
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Growth ofHuman Tumor Cells in SCID Mice.
￿
SCID mice
were injected either intraperitoneally or intravenously with
the human B cell lymphoma cell lines SU-DHL4 and OCl-
Ly8. These human tumor cell lines were selected because both
harbor a t(14;18) chromosomal translocation, allowing better
detection of small numbers ofcells by PCR assay. All animals
injected with 106 or 107 SU-DHL4 cells either died within
100 d after injection or were killed when suffering from tumor
signs. Survival of the mice was dependent on the cell dose
injected. This was true for intraperitoneal (Fig. 3 A) as well
as for intravenous (Fig. 3 B) injection of tumor cells. Animals
injected with 105 or less SU-DHL4 cells intravenously had
no tumor signs and survived for >100 d after injection (Fig.
3 B) . There was no significant difference in survival between
intravenous and intraperitoneal injection usingeither cell line
(data for OCI-Ly8 not shown) . Mice injected intravenously
often developed hind leg paralysis, a sign known to occur
Table 2.
￿
Effects of Effector Cells Generated by Various Protocols
on Hematopoietic Precursor Cell Growth
In Vivo Evaluation of Cytokine-induced Killer Cells
CPU-GM colonies were stimulated with 15% placental conditioned me-
dium (PCM), plated in triplicate in 0.25 ml methylcellulose medium,
and scored on day 10. No colonies formed in the absence of PCM.Results
are reported as number of colonies per 5 x 10^ cells plated. CIK cells
were induced with IFN-y, and added 1 d before IL-2, anti-CD3, and
IL-1, as describedin Materials andMethods. Results arepresentedas mean
value ± SEM.
IL-2 + anti-CD3 + IL-1 +
IFNy at
NS
same time as IL-2 Protocol
No.
CFU-GM
of
colonies
Percent of
untreated control
IL-2 + anti-CD + IL-1 + p 5 .05 BM 47 .3 ± 5.0 100 IFNy 24 hrs after IL-2W, 1 L A I I BM + IL-2 42 .3 ± 2.1 89 .4
0 10 20 30 40 50 60 70 BM + LAK 46 .3 ± 1.7 97 .9
LYTIC UNITS BM + CIK 35 .3 ± 3.8 74 .6
Table 1. Effect ofVarious Protocols on
Regimen
Cytotoxicity and
LU/106
Cell Proliferation
cells Cell number
Total LU
per culture
Log cell kill
(range)
x 10,
11-2 25 ± 1.5 19 ± 2.0 475 1 (0.5-1 .5)
IL-2 plus anti-CD3 28 ± 0.8 754 ± 31 .8 21,112 ND
IFN--y + anti-CD3 + IL-2 + IL-1 49 ± 0.6 708 ± 11 .1 34,692 3 (2.5-3 .5)100r
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Figure 3.
￿
(A) Dose dependence ofintraperitoneal injectionofSU-DHL4
cells into 12 SCID mice. Either 50-100 x 106 or 1-45 x 106 tumor cells
were injected. (B) Dose dependence of intravenous injection ofSU-DHL4
cells into 12 SCID mice. Either 2-10 x 106, 0.5-1 x 106, or <0.1 x
106 tumor cells were injected. Shown are data from three different ex-
periments.
after injection ofmurine B cell lymphomas (31). In vivo, SU-
DHL4 cells were more aggressive than OCI-Ly8 cells. In
14 ofthe 28 injected animals, tumor masses could be detected
macroscopically (Table 3), mostly in the lower abdomen.
Tumor nodules measured 1-3 cm in diameter, and were found
either in the mesentery, paraaortic, or retroperitoneal loca-
tions. Because of the large tumor masses enteric obstructions,
Table 3.
￿
Growth of Two Diferent Human B Cell,Lymphoma Cell Lines in SCID Mice after Intravenous or Intraperitoneal Injection
of Various Numbers of Tumor Cells
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ileus and urine retention were found. In addition, spleno-
megaly was found in three cases. Enlarged lymph nodes were
found in mesenteric and retroperitoneal areas. To test the effect
of pre-irradiation on tumor cell engraftment, four animals
received whole body irradiation with 175 cGy 1 d before in-
jection with the lymphoma cells. No difference was noted
in survival as compared with the nonirradiated animals.
Histopathology.
￿
Frozen sections of the tumor tissue and
various other tissues (bone marrow, spleen, lymph nodes, and
lung) were prepared. The tumor tissue was stained with
Mayer's haematoxilin. Masses of lymphoid-like cells could
be demonstrated (Fig. 4 A).
Leu-12 (CD19)-positive cells could be detected in all tissues
(for tumor shown in Fig. 4 B). However, it should be noted
that there was some nonspecific background staining in SCID
mice that had not been injected with tumor cells, however,
the staining was stronger in mice injected with tumor cells.
No cells were found to be Leu-4 (CD4) positive (Fig. 4 C).
Clonogenic TumorAssay.
￿
The cloning efficiency ofthe SU-
DHL4 cell line was 1-5%, as reported elsewhere (26). When
cells isolated from murine tumor tissue were tested in a clono-
genic assay, there was no significant difference in clonoge-
nicity as compared with freshly cultured SU-DHL4 cells (data
not shown).
Detection oft(14;18}carrying Cells in Tissue by PCR.
￿
Con-
ditions have been established for performing PCR to detect
minimal residual tumor cells in single cell suspensions and
in murine tissues. Results of a dilution series to demonstrate
the sensitivity of the t(14;18) PCR assay for SU-DHL4 cells
are shown in Fig. 5. Three major amplification products were
detected at -230, -600, and -1,300 bp. The larger am-
plification products are in general lost first at increasing tumor
cell dilutions. A semi-quantitative estimate ofthe tumor cell
concentration is therefore possible. A signal could be detected
to a 10 -5 dilution of SU-DHL4 cells, which corresponds to
DNA from less than five tumor cells in the reaction.
PCR was performed on various murine tissues from animals
after injection of SU-DHL4 or OCI-Ly8 cells. In general,
positive signals were found in DNA prepared from splenic
tissue, when the mice were killed between days 9 and 50.
Lymph node involvement, which was the most common
Tumor cells were detected by using PCR to amplify a t(14;18) chromosomal translocation in tissues (lymph nodes, spleen, lung, liver, bone marrow,
and kidney) from SCID mice injected with SU-DHL-4 or OCI-Ly8 cells .
Tumor
type
Method of
- tumor injection
No. of cells
injected
Mice with macroscopic
tumor per mice
inoculated
Mice with tumor
cell detection
by PCR
SU-DHL-4 i.p. 2 x 106-108 4/12 6/6
i.v. 5 x 105-101 4/7 4/4
OCI-Ly8 i.p. 5 x 105-3 x 10' 3/5 3/3
i.v. 106-10' 3/4 3/4144
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Figure 4 .
￿
Histopathology ofa frozen section of
aSCI :) mouse injected with a human Blymphoma
cell line. A SCID mouse was injected intraperi-
toneally with 106 SU-DHI>4 cells and killed on
day 115 after injection . At that time, a mass was
palpable in the lower abdomen . Frozen sections
were prepared from the excised tumor by standard
technique (see Materials and Methods) . (A) Un-
stained section of the tumor after fixation with
glutaraldehyde . (B) Frozen section stained with a
mAb against a human B cell antigen, Leu-12 . (C)
Frozen section stained with amAb against a human
Tcell antigen, Leu-4. Staining was performed using
the streptavidine alkaline phosphatase method.Figure 5 .
￿
Dilution series for detection of tumor cells by PCR . Various
numbers of SU-DHL4 cells were added to mononuclear cells derived from
human peripheral blood at the indicated dilutions. After preparation of
DNA,PCRwas performed using 2 Fig ofDNA. Molecular weight markers
are as indicated.
finding, was detected throughout the time course, but PCR-
amplified t(14;18) products were more prominent at later
stages . A typical result after intraperitoneal injection ofSU-
DHL4 cells is shown in Fig. 6 . Detection of tumor cells was
enhanced using PCR as compared with macroscopic tumor
detection (Table 3) .
In Vitro Purging ofSCID Bone Marrow.
￿
CIK cells were
used in the SCID model for the purpose of treating bone
Figure 6 .
￿
The use ofPCR to detectSU-DHL4 tumor cells in murine
tissues . A SCID mouse was injected intraperitoneally with 106 SU-DHL4
cells on day 0 . The mouse was killed on day 115 . At that time, the animal
appeared ill and had a large palpable mass in the lower abdomen . Tumor
cells were detected by using PCR to amplify the t(14;18) chromosomal
translocation in tissueDNA. Murine tissues examined include lymph node
(lane 1), spleen (lane 2), lung (lane 3), liver (lane 4), and bone marrow
(lane S) . DNA from regular SU-DHL4 cells was amplified in lane 6 as
a control, Theband in lane 4 does not represent a typicalband for a t(14;18)
translocation, and was scored as not interpretable .
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marrow in vitro in an effort to remove tumor cells. To carry
out these experiments, 10 7 SCID bone marrow cells were
contaminated with either 106 or 10 7 SU-DHL4 cells. The
cytotoxic cells were added at an E/T ratio of 20:1 . The cel-
lular mixtures were incubated in vitro for 24 h and then in-
jected into SCID mice that had undergone long bone irradi-
ation . Control animals, which received unpurged contaminated
bone marrow (curves 1 and 2 in Fig. 7), all died within 40
d. In contrast, when bone marrow cultures contaminated with
either 106 (curve 4) or 107 (curve 3) SU-DHL4 cells, which
had been treated with CIK cells, were injected, the majority
of animals showed no signs of tumor cell growth for >100
d . In animals that died of tumor growth, a positive t(14;18)
PCR signal could be recovered from a variety of tissues (Fig.
6) . When SCID mice were injected with CIK cells alone,
all animals survived for >100 d (data not shown) . Interest-
ingly, treatment of contaminated bone marrow with LAK
cells generated with 11,2 alone had no protective effect on
survival of animals (only four mice tested ; data not shown) .
These data indicate that the CIK cells effectively lysed at least
1.5 logs of tumor cells and that the SCID mouse model system
could be used to study the efficacy of this treatment approach .
Hematopoietic engraftment ofhuman cells can not yet be
routinely studied in the SCID mice . In an effort to demon-
strate hematopoietic engraftment ofBALB/c marrow cells,
the BALB/c-specific IgD H chain allotype mAb AMS 9.1
was used . SCID mice that received BALB/c bone marrow
treated in vitro with CIK cells had evidence for hematopoi-
etic engraftment, as demonstrated by the emergence ofAMS
9.1-positive cells 4 wk after transplantation (Fig . 8) . Animals
were rechecked for engraftment on day 100, when they were
still found to be AMS 9.1 positive . All animals survived
>150 d .
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Figure 7 .
￿
Effect ofin vitro purging ofSCID bone marrow on survival
of SCID mice. Either 106 (n = 10) or 107 (n - 10) SU-DHL4 human
lymphoma cells were incubated with human CIK cells at a ratio of 20:1 .
As controls, no effector cells were added (107 SU-DHL4 cells, n = 9 ;
10 6 tumor cells, n = 4) . To resemble the situation of purging bone
marrow, 10 7 bone marrow cells from SCID mice were added at the same
time. These cell mixtures were injected intravenously into SCID mice 3-48
h after irradiation of the long legs with 400 cGy, as described in Materials
and Methods.BALB/c
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In this report, a murine SCID/human lymphoma model
has been developed to evaluate the efficacy of cultured cyto-
toxic cells to specifically lyse a human tumor cell line. An
experimental protocol was developed in an effort to expand
and enhance the cytotoxicity ofeffector cells directed against
non-Hodgkin's lymphoma cell lines. The B cell lymphoma
cell line SU-DHL4 was used because it has a t(14;18) chro-
mosomal marker that allows for sensitive detection using PCR.
These cells have been used for testing cytotoxic activity of
LAK cells in a S'Cr release assay, a clonogenic assay, and
PCR has been used to monitor the effectiveness of ex vivo
tumor cell purging with antibodies and complement (26).
In Vivo Evaluation of Cytokine-induced Killer Cells
Figure 8.
￿
Engraftment ofBALB/c bone marrow when
injected into SCID mice together with human CIK cells.
4 wk after intravenous injection ofSCID mice with bone
marrow cells from BALB/c mice, animals were tested for
engraftment ofBALB/c bone marrow cells. BALB/c bone
marrow cells had been cocultured with human effector
cells and human lymphoma cells, as described in Materials
and Methods. Peripheral bloodwas taken from these mice,
andcells were Ficoll separated and stained for IgD H chain
allotype using the mAb AMS 9.1 (30). A typical example
is shown here (SCID d8). Controls include staining pat-
terns from a BALB/c mouse (BALB/c) and from a normal
SCID mouse (normal SCID).
LAK cells can be used as cytotoxic effector cells for adop-
tive immunotherapy (32, 33). Large numbers of LAK cells
are necessary for effective immunotherapy in vivo (2, 34).
In some patients, it is difficult to obtain sufficient effector
cell numbers, for example, after chemotherapy. Standard II,
2-activated LAK cells have modest cytotoxicity against lym-
phomacells. Cells with high cytotoxic activity may have clin-
ical potential, for example, for in vitropurging ofbone marrow
in the context of autologous bone marrow transplantation.
Therefore, our goal was to increase the cell number and en-
hance the cytotoxic activity of these populations of cells.
mAbs directed against CD3 have been shown to triggerproliferation of T cells. This increase is in cell number only,
as no increase in cytotoxic activity on a per cell basis was
found (4). We have explored the use of other cytokines in
an effort to enhance cellular toxicity. The recombinant
cytokines studied include IFN-y, 11,1, and TNF. The time
course ofIFN-y addition was found to be crucial in enhancing
cytotoxic activity. The addition of IFN-y after the addition
of IL2 reduces cytotoxicity (4), however, the reverse order
led to an increase in cytotoxicity. This is in agreement with
other reports (35-37). After exposure to IFN-y, the expres-
sion of receptor sites for 1172 on PBMC increases (36). The
enhanced rytotoxic activity may be due to the induction of
IL-2 receptors on the effector cells, resulting in a more efficient
activation or recruitment of additional cell populations that
are not activated by IL2 alone (35). Similarly, Ellis et al. (38)
have shown that IFN-y induces classic LAK activity and plays
a participatory role in the optimal induction of LAK cells
by IL2.
Furthermore, the combination of IFN-y and anti-CD3
combines the proliferative effect of the anti-CD3 treatment
with the increase in cytotoxicity by IFN-y. The addition of
1171 improved the cytotoxic effect slightly, but significantly.
IL-1 has also been shown to play an important role in in-
ducing the expression of IL2 receptors (39) . Using this com-
bination ofcytokines, a cell kill of2.5-3.5 logs was achieved,
as measured by a clonogenic assay. This level of log cell kill
compares favorably with current bone marrow purging regi-
mens, which remove 2-4 logs of tumor cells from bone
marrow (40). For example, with a cocktail ofmAbs and com-
plement after two rounds oftreatment ofB cell lymphomas,
a log cell kill of 3 was reached (26). Using the protocol de-
scribed here in combination with current methods of bone
marrow purging, it may be possible to improve the efficacy
of the purging process.
The effect of LAK cellson humanbone marrow precursor
cells is still controversial. Savary et al. (41) have shown that
LAK cells are potent inhibitors of marrow progenitor cells.
Van den Brink et al. (42) demonstrated that growth of colony-
forming cells is not impaired after incubation with LAK cells.
The CIK effector cells described here show slight impair-
ment ofgrowth of normal hematopoietic colony-forming cells.
This impairment could be mediated by various cytokines pro-
duced by the effector cells, like TNF, lymphotoxin, and IFN.
These cytokines have been shown to inhibit bone marrow
progenitor cells in vitro (43).
The majority of effector cells described here have T cell
phenotype and therefore resemble TIL (44). Although most
of the lymphocytes in TIL cultures are CD3+, the rytotoxic
cells are primarily Leu-19+, and can be either of the CD3'
or CD3 - phenotype (45). LAK cells have been shown to
be mostly of the NK cell phenotype. In comparison with
TIL, our effector cells need no contact with tumor cells for
stimulation and proliferation. Although the majority of CIK
cells expresses CD3 and the TCR-cx/a killing by CIK cells
seems to be non-MHC restricted. Non-MHC-restricted T
cells have already been described by Lanier et al. (46). More
experiments about the mechanism of killing by CIK cells
are being performed.
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In this study, we have used SCID mice as a model for in
vivo growth of human B lymphoma cell lines. These mice
can be used for evaluating novel therapeutic approaches for
the treatment of lymphoma. The B cell lymphoma cell line
SU-DHL4 grows in these animals producing tumors in a
dose-dependent fashion.
To detect tumor cells in the SCID mouse model, several
approaches were used. The cells tested here are of B cell lin-
eage and therefore bear human B cell antigens on their cell
surface. Unfortunately, there is a surprising degree of unspecific
staining of SCID mouse nonlymphoid cells (47), including
tests with anti-human B cell mAbs (47, 48). This phenomenon
has not been encountered in normal mice. Therefore, FACS®
analysis with mAbs against human B cell markers is ham-
pered in SCID mice (47). These tumor cells can also be de-
tected using the t(14;18) chromosomal translocation. This
translocation could be readily detected by PCR of murine
tissues containing SU-DHIr4 tumor cells. This assay is ex-
tremely sensitive and a single tumor cell in 105 normal cells
can be detected. With such a high degree of sensitivity, PCR
is an ideal technique to detect minimally contaminated tissues.
To ensure that the loss of the PCR signal was not due to
technical artifacts, murine (3 actin primers were added to the
reaction mix. This resulted in the amplification of 0 actin
transcripts, indicating that the PCR itself was functioning
properly.
CIK cells generated in vitro were tested in vivo using this
murine SCID/human lymphoma model. The addition of a
20-fold excess of cytotoxic cells had a protective effect on sur-
vival of these animals. This reflects at least a 1.5-2-log cell
kill, as tested by this in vivo model, as injection of at least
0.5 x 106 tumor cells is required for tumor cell growth in
the mice.
To test whether the CIK cells prevent bone marrow cells
from engrafting, we injected rytotoxic cells together with
BALB/c bone marrow cells into SCID mice. We found that
BALB/c bone marrow engrafted in all cases tested, as mea-
sured by a mAb against an Ig H chain allotype. Thus, this
populationof cells seemsto have low toxicity against murine
bone marrow stem cells. In addition, there was minimal tox-
icity against human hematopoietic precursors. To date it is
not yet possible to monitor for human hematopoietic engraft-
ment. A new model system has been developed (Dr. C. Baum,
personal communication), and the effect of CIK cells on
human hematopoietic engraftment will be tested using his
model.
It is important to keep in mind that so far only in vitro
purging has been tested in this model, and that these mice
had no tumor cell burden before injection oftumor and CIK
cells. Our goal was to test these cells as a regimen for purging
ofbone marrow cells for autologous bone marrow transplan-
tation. It remains to be seen if the CIK cells will be able
to cytoreduceestablished minimal residual disease. However,
this protocol may have an important impact on the use of
rytotoxic cells as adoptive immunotherapy, for example, to-
gether with autologousbone marrow transplantation. In this
context, it is important that these cells have little toxic effects
on hematopoietic precursor cells. The higher number ofeffector cells and the increase in efficacy of these cells could
lead to a lower dose of 11,2 necessary for treatment. This
may also decrease the toxicity of LAK cell therapy, which
has been a major problem.
In conclusion, we have developed anew protocol that leads
to high cell numbersof effector cellswith increasedcytotox-
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